iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease... Show more
iRhythm Technologies, a digital cardiac monitoring specialist now operating as iRhythm Holdings, is best known for its Zio patch, which enables up to 14 days of long-term continuous electrocardiogram monitoring. Its competitive edge rests on proprietary, AI-trained arrhythmia-detection algorithms, deep clinical evidence, a broad clinician installed base, and workflow integrations with electronic health record (EHR) systems. Those integrations have historically lifted prescribing patterns meaningfully, reinforcing a network effect that rivals struggle to replicate quickly.
Strategically, the company is extending beyond its core patch franchise into the faster-growing MCT segment through Zio AT and the forthcoming Zio MCT, while pushing into value-based care and international markets, including Europe and Japan. The medium-term question is whether this diversification can broaden the revenue base fast enough to offset structural risks: dependence on government and commercial reimbursement, tariff exposure from overseas manufacturing, and lingering FDA quality-system remediation obligations. Execution on these fronts will define the next phase of market positioning.
The most consequential catalyst is the regulatory clearance and commercial launch of Zio MCT, submitted under an FDA 510(k) premarket notification pathway in September 2025. A successful launch would let iRhythm compete more directly for a larger MCT opportunity while preserving the high-growth Zio AT franchise.
Resolution of the company's FDA warning-letter remediation is another swing factor, as completing quality-system fixes could reduce compliance costs and clear a regulatory overhang. Reimbursement decisions also matter: updates from the Centers for Medicare & Medicaid Services (CMS) and Medicare Administrative Contractors (MACs, private insurers that process Medicare claims) directly shape pricing and volume visibility. Additional value-based care partnership signings, progress in Japan toward premium reimbursement, and full-year guidance for 2026 and 2027 round out the catalyst set.
On analyst ratings, consensus remains firmly positive, with a "Strong Buy" profile and an average price target near $171 (ranging from roughly $140 to $196, according to recent S&P Global data). That said, the picture is more nuanced than a headline upgrade: firms including J.P. Morgan, Bank of America, Wells Fargo, and Evercore ISI trimmed price targets during 2026, reflecting a mix of optimism about fundamentals and caution about valuation and reimbursement timing.
iRhythm's trajectory is tightly linked to the shift toward remote, virtual, and preventive care, a structural tailwind accelerated by an aging population and rising cardiovascular disease prevalence. Adoption of AI-assisted diagnostics and value-based care models, which reward early detection and avoid costly downstream events, favors proactive cardiac monitoring as a category.
Macro forces cut both ways. As a high-growth, previously loss-making med-tech company, iRhythm's valuation multiple is sensitive to interest rates; a higher-for-longer rate environment has weighed on richly valued growth stocks even when operating results are strong. On the cost side, tariffs on Chinese-manufactured components have added modest gross-margin pressure, while reimbursement policy from CMS and MACs remains the single most important pricing determinant. Inflation in clinical and manufacturing labor can also compress margins if not offset by volume leverage and automation.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to surface developing trends, evaluate potential breakouts or reversals, and allow users to explore predictions across a wide range of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors monitoring the evolving outlook on IRTC and comparable names, the Trend Prediction Engine offers a data-driven way to track directional signals as catalysts unfold.
For the remainder of 2026 and into 2027, the strategic narrative centers on whether Zio MCT can convert iRhythm's low-teens MCT share into a meaningfully larger position. Management has indicated that every ten percentage points of incremental MCT share could translate to roughly $100 million in annual revenue, underscoring the scale of the opportunity. Consensus forecasts point to revenue near $892 million for 2026, a year-over-year increase of about 19%, with a further step toward roughly $1.04 billion in 2027 and a transition to positive earnings per share.
Longer term, margin sustainability will depend on achieving the company's 72–73% gross-margin target by 2027 while keeping operating leverage intact as it scales manufacturing and clinical operations. International expansion, value-based care penetration, and EHR-driven workflow adoption represent the primary market-expansion levers. Competitive threats from larger diversified med-tech players, reimbursement volatility, and the durability of the growth-stock valuation premium are the principal counterweights. Capital allocation priorities—balancing growth investment against the emerging FCF inflection—will increasingly shape investor sentiment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PYPY | 26.30 | 0.40 | +1.53% |
| YieldMax PYPL Option Income Strategy ETF (PYPY) | |||
| VMSB | 47.96 | N/A | N/A |
| Voya Multi-Sector Income ETF (VMSB) | |||
| FSEP | 56.87 | -0.08 | -0.14% |
| FT Vest U.S. Equity Buffer ETF - September (FSEP) | |||
| TNUK | 20.58 | -0.23 | -1.12% |
| Tortoise Nuclear Renaissance ETF | |||
| ASTX | 2.43 | -0.30 | -11.13% |
| Tradr 2X Long ASTS Daily ETF (ASTX) | |||
A.I.dvisor indicates that over the last year, IRTC has been loosely correlated with STE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IRTC jumps, then STE could also see price increases.
| Ticker / NAME | Correlation To IRTC | 1D Price Change % | ||
|---|---|---|---|---|
| IRTC | 100% | -1.76% | ||
| STE - IRTC | 48% Loosely correlated | +4.29% | ||
| INGN - IRTC | 45% Loosely correlated | +1.25% | ||
| OFIX - IRTC | 44% Loosely correlated | +3.31% | ||
| SYK - IRTC | 44% Loosely correlated | -0.88% | ||
| MDT - IRTC | 42% Loosely correlated | +1.85% | ||
More | ||||
| Ticker / NAME | Correlation To IRTC | 1D Price Change % |
|---|---|---|
| IRTC | 100% | -1.76% |
| Health Services category (238 stocks) | 6% Poorly correlated | -1.01% |
| Medical/Nursing Services category (138 stocks) | 5% Poorly correlated | -1.10% |
a provider of monitoring and diagnostic solutions for detection of cardiac arrhythmias
Industry MedicalNursingServices
The RSI Indicator for IRTC moved out of oversold territory on November 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 19 of the 23 cases the stock moved higher. This puts the odds of a move higher at 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRTC advanced for three days, in 254 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IRTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 191 of 241 cases where IRTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRTC as a result. In 66 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for IRTC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 40 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
IRTC moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRTC crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.990) is normal, around the industry mean (4.142). IRTC has a moderately low P/E Ratio (-214.810) as compared to the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.398) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IRTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.